(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.36%) $83.55
(-1.16%) $1.619
(-0.04%) $2 346.30
(0.89%) $27.50
(0.29%) $924.80
(0.26%) $0.934
(0.41%) $11.00
(0.08%) $0.800
(0.00%) $92.17
Quarter results tomorrow
(bmo 2024-04-29)
Expected move: +/- 4.43%
Live Chart Being Loaded With Signals
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene...
Stats | |
---|---|
Šios dienos apimtis | 73 164.00 |
Vidutinė apimtis | 222 948 |
Rinkos kapitalizacija | 46.35B |
EPS | INR0 ( 2024-04-13 ) |
Kita pelno data | ( INR0 ) 2024-04-29 |
Last Dividend | INR1.000 ( 2023-02-08 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 25.77 |
ATR14 | INR0.544 (0.11%) |
Tūris Koreliacija
Aarti Drugs Limited Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
BBL.NS | 0.955 |
RBLBANK.NS | 0.954 |
AIRAN.NS | 0.949 |
PGHH.NS | 0.944 |
KELLTONTEC.NS | 0.94 |
HPL.NS | 0.94 |
PREMEXPLN.NS | 0.939 |
SJVN.NS | 0.938 |
TWL.NS | 0.936 |
POLYCAB.NS | 0.934 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
LTGILTBEES.NS | -0.947 |
SINTEX.NS | -0.924 |
RAJRILTD.NS | -0.922 |
BOHRAIND.NS | -0.92 |
RAJVIR.NS | -0.911 |
BGLOBAL.NS | -0.906 |
IRISDOREME.NS | -0.906 |
OMAXE.NS | -0.905 |
JPINFRATEC.NS | -0.903 |
SRPL.NS | -0.901 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Aarti Drugs Limited Koreliacija - Valiuta/Žaliavos
Aarti Drugs Limited Finansinės ataskaitos
Annual | 2022 |
Pajamos: | INR27.16B |
Bruto pelnas: | INR8.28B (30.47 %) |
EPS: | INR17.96 |
FY | 2022 |
Pajamos: | INR27.16B |
Bruto pelnas: | INR8.28B (30.47 %) |
EPS: | INR17.96 |
FY | 2022 |
Pajamos: | INR24.89B |
Bruto pelnas: | INR5.04B (20.24 %) |
EPS: | INR22.12 |
FY | 2021 |
Pajamos: | INR21.55B |
Bruto pelnas: | INR6.00B (27.86 %) |
EPS: | INR30.09 |
Financial Reports:
No articles found.
Aarti Drugs Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR1.000 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.150 | 2003-11-13 |
Last Dividend | INR1.000 | 2023-02-08 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 32 | -- |
Total Paid Out | INR15.88 | -- |
Avg. Dividend % Per Year | 0.23% | -- |
Score | 2.13 | -- |
Div. Sustainability Score | 4.77 | |
Div.Growth Potential Score | 3.35 | |
Div. Directional Score | 4.06 | -- |
Year | Amount | Yield |
---|---|---|
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.250 | 0.18% |
2019 | INR0.250 | 0.17% |
2020 | INR3.00 | 2.03% |
2021 | INR0 | 0.00% |
2022 | INR1.000 | 0.18% |
2023 | INR1.000 | 0.22% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
POONAWALLA.NS | Dividend Junior | 2023-07-18 | Sporadic | 21 | 0.21% | |
JTLIND.NS | Dividend Junior | 2023-08-04 | Insufficient data to determine frequency | 2 | 0.04% | |
DPABHUSHAN.NS | Dividend Junior | 2023-09-22 | Annually | 3 | 0.15% | |
ABBOTINDIA.NS | Dividend Junior | 2023-07-20 | Annually | 17 | 0.52% | |
SPIC.NS | Dividend Junior | 2023-09-20 | Annually | 3 | 0.70% | |
MPHASIS.NS | Dividend Knight | 2023-07-05 | Annually | 20 | 1.43% | |
HESTERBIO.NS | Dividend Junior | 2023-09-13 | Annually | 10 | 0.31% | |
BIRLACABLE.NS | Dividend Junior | 2023-09-04 | Sporadic | 11 | 0.93% | |
RAYMOND.NS | Dividend Junior | 2023-06-23 | Sporadic | 29 | 0.15% | |
KOTARISUG.NS | Dividend Junior | 2023-08-03 | Sporadic | 11 | 0.58% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0680 | 1.500 | 8.64 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.150 | 1.500 | 9.44 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 8.41 | 1.000 | 8.00 | 8.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 10.96 | 2.00 | 4.52 | 9.04 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.322 | 1.000 | 7.96 | 7.96 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.105 | 1.000 | 9.91 | 9.91 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 25.72 | 1.000 | 7.50 | 0 | [1 - 100] |
returnOnEquityTTM | 0.150 | 2.50 | 9.64 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 9.04 | [0 - 30] |
dividendYielPercentageTTM | 0.198 | 1.500 | 5.04 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.362 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0380 | 1.000 | -1.550 | 0 | [0.1 - 0.5] |
Total Score | 3.35 |
Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.